Soaring Eagle Acquisition Corp. (NASDAQ:SRNG) has secured shareholder approval of its combination with cell programming company Ginko Bioworks at a shareholder vote this morning.
The SPAC did see about 49% of its trust redeemed in the vote, however. This will still provide about $1.6 billion in proceeds to Ginko Bioworks, including $858 million from Soaring Eagle’s remaining trust, which is plenty to fulfill the transactions’ minimum cash condition of $1.25 billion. Overall, this is a better-than-average result compared to the redemption rates of the past month, but still more than might be expected for such a prestigious deal.
Soaring Eagle expects to complete the transaction on September 16. The combined company’s shares and warrants are expected to begin trading on the NYSE the following day under the symbols “DNA” and “DNA.WS”, respectively.
Ginko Bioworks uses genetic engineering to create bacteria for a range of industries with a focus on strain improvement, enzyme discovery, new product development, biosecurity, and mammalian cell engineering. Most recently, Ginko Bioworks announced its platform had achieved breakthroughs in manufacturing mRNA vaccines and rare forms of cannabis compounds.
About 75% of shares participated in Soaring Eagle’s vote and 97% voted in favor of the transaction. Vote tallies on any additional measures will be made available once the SPAC files its 8-K on the meeting.
ADVISORS
- Allen & Company LLC and Morgan Stanley & Co. LLC are acting as financial advisors to Ginkgo.
- Latham & Watkins LLP is acting as legal advisor to Ginkgo.
- Wachtell, Lipton, Rosen & Katz is acting as legal advisor to Ginkgo with respect to certain corporate governance matters.
- Goldman Sachs & Co. LLC is acting as financial advisor to Soaring Eagle.
- White & Case LLP is acting as legal advisor to Soaring Eagle.
- Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Allen & Company LLC served as placement agents for Soaring Eagle on the PIPE transaction.
Terms Tracker for the Week Ending May 23, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Another solid week for SPAC IPO trading. Five more IPOs priced, bringing May’s total to 18 and the YTD tally to 49. That’s just eight...
Pelican Acquisition Corp. (NASDAQ:PELIU) announced the pricing of its $75 million IPO and its units began trading on the Nasdaq under the symbol “PELIU”, Friday, May 23, 2025. The new SPAC aims to combine with a technology company with a defensible market position that would benefit from being publicly traded in the US. Pelican’s management...
Cohen Circle II (NASDAQ:CCIIU) has filed for a $220 million SPAC marking the second wave of the Betsy Cohen team’s return to the market in the burgeoning 2024/2025 cycle. The new SPAC brings slightly less warrant coverage than its predecessor Cohen Circle I (NASDAQ:CCIR) with a 1/4 warrant in each of its units as opposed...
A Paradise (NASDAQ:APADU) has filed for a $200 million SPAC to get a fresh Asia-focused vehicle on the road with a leader that has steered several SPACs before. The new SPAC continues underwriter Cohen & Company’s warpath as its 15th SPAC put on file this year, with the firm’s 12th SPAC IPO debut set for...
On this week’s SPACInsider REPLAY, we revisit a 2022 conversation with Harry Sloan of the Eagle SPACs. At the time, Harry had already completed seven SPACs and was closing in on his eighth. As markets cooled and the SPAC boom waned, Harry offered a prescient take on where the market was headed—and what a “post-boom”...